CZMWF (Carl Zeiss Meditec AG) EBIT: $222 Mil (TTM As of Dec. 2025)


CZMWF Carl Zeiss Meditec AG CZMWF
70 GF Score
Price $31.42
GF Value $85.82
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG EBIT?

Carl Zeiss Meditec AG CZMWF 70 EBIT is $222 Mil as of Dec. 2025. GuruFocus rates CZMWF with a GF Score™ of 70/100 and a GF Value™ of $85.82 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Carl Zeiss Meditec AG's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $222 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carl Zeiss Meditec AG's annualized ROC % for the quarter that ended in Dec. 2025 was 0.13%. Carl Zeiss Meditec AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Carl Zeiss Meditec AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.85%.

Carl Zeiss Meditec AG  (OTCPK:CZMWF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carl Zeiss Meditec AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=4.684 * ( 1 - 0% )/( (3662.237 + 0)/ 1 )
=4.684/3662.237
=0.13 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3994.567 - 300.326 - ( 32.004 - max(0, 638.276 - 1492.894+32.004))
=3662.237

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Carl Zeiss Meditec AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.368/( ( (402.527 + max(308.115, 0)) + (0 + max(0, 0)) )/ 1 )
=9.368/( ( 710.642 + 0 )/ 1 )
=9.368/710.642
=1.32 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(245.32 + 583.312 + 89.428) - (300.326 + 0 + 309.619)
=308.115

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Carl Zeiss Meditec AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=221.85/2827.775
=7.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG EBIT Related Terms

Carl Zeiss Meditec AG EBIT Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG EBIT Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 409.90 408.99 456.58 299.99 258.82

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.27 78.26 54.97 86.29 2.34

CZMWF vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's EV-to-EBIT falls into.


CZMWF
70GF Score
Carl Zeiss Meditec AG CZMWF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $222 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $222 Mil mean?
Carl Zeiss Meditec AG (CZMWF) has a EBIT of $222 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carl Zeiss Meditec AG.
Is Carl Zeiss Meditec AG's EBIT too high?
Carl Zeiss Meditec AG's current EBIT is $222 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EBIT compare to ISRG and BDX?
Carl Zeiss Meditec AG's EBIT of $222 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Carl Zeiss Meditec AG. Carl Zeiss Meditec AG's current EBIT is $222 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (CZMWF) is currently considered Significantly Undervalued. The stock's GF Value™ is $85.82, compared to a current price of $31.42 — trading 63.4% below its estimated fair value. The current EBIT is $222 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Carl Zeiss Meditec AG (CZMWF), the current EBIT is $222 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (CZMWF) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of $31.42 is trading 63.4% below its estimated GF Value™ of $85.82. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for CZMWF:

  • EBIT: $222 Mil
  • GF Value™: $85.82 vs. price of $31.42 (63.4% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the CZMWF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for CZMWF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.42
Price
$85.82
GF Value